SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001867096-22-000092
Filing Date
2022-06-09
Accepted
2022-06-09 17:14:18
Documents
2
Period of Report
2022-06-08

Document Format Files

Seq Description Document Type Size
1 FORM 4 wf-form4_165480924524079.html 4  
1 FORM 4 wf-form4_165480924524079.xml 4 5756
2 HALKUFF DAWN POA ex-24.htm EX-24 2989
  Complete submission text file 0001867096-22-000092.txt   10133
Mailing Address C/O XERIS PHARMACEUTICALS 180 N. LASALLE ST., STE. 1800 CHICAGO IL 60601
Business Address
HALKUFF DAWN (Reporting) CIK: 0001743658 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-40880 | Film No.: 221006881

Mailing Address 180 N. LASALLE STREET, SUITE 1600 CHICAGO IL 60601
Business Address 180 N. LASALLE STREET, SUITE 1600 CHICAGO IL 60601 844-445-5704
Xeris Biopharma Holdings, Inc. (Issuer) CIK: 0001867096 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations